Investor Relations Captor Therapeutics ®
Completion of the book-building process for the offering of new series P bearer shares and determination of the issue price for series P shares
Current report no. 43/2023
Drafting date: 22 September 2023.
Subject: Completion of the book-building process for the offering of new series P bearer shares and determination of the issue price for series P shares
Legal basis: Article 17(1) MAR - confidential information.
The Board of Directors of Captor Therapuetics S.A The Management Board of Captor Therapeutics S.A., based in Wrocław, Poland (the "Company"), with reference to: (i) current report no. 41/2023 dated 21 September 2023 and current report no. 42 dated 21 September 2023, announces that on 22 September 2023 the book building process, conducted by Trigon Dom Maklerski S.A., Trigon Investment Banking spółka z ograniczoną odpowiedzialnością & Wspólnicy sp. k. and Powszechna Kasa Oszczędności Bank Polski S.A. Branch- Biuro Maklerskie in Warsaw ("Investment Firms"), the book-building process for no more than 400,000 P-series ordinary bearer shares of the Company ("P-series Shares") issued pursuant to the Management Board's Resolution No. 2 of 21 September 2023 on increasing the Company's share capital within the limits of the authorised capital through the issue of P-series shares, with the exclusion of pre-emptive rights and on amending §6.1 of the Company's Articles of Association.
Accordingly, on 22 September 2023, after considering the results of the book-building process and the recommendations of the Investment Companies, the Board of Directors of the Company set the final issue price of the Series P Shares at PLN 100 (one hundred zlotys) per Series P Share and decided to make offers to investors to subscribe for the Series P Shares at the set issue price in relation to all 400,000 (four hundred thousand) Series P Shares. At the same time, the Company and the Investment Companies entered into a price annex to the share placement agreement confirming the above arrangements and determining the initial allocation of the Series P Shares.
This current report has been prepared solely for the purpose of fulfilling the obligations arising from Article 17(1) of Regulation EU No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse Regulation and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC MAR, as the Company considered the information on the commencement of the Accelerated Book-building Process for the Series P Shares as meeting the criteria of confidential information within the meaning of Article 7 MAR. This report is in no way intended to promote, directly or indirectly, the offer, subscription or purchase of the P Shares and does not constitute advertising or promotional material prepared or published by the Company for the purpose of promoting the P Share Offer or to encourage investors, directly or indirectly, to purchase or subscribe for the P Shares.